The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|May 24, 2018
Elligo Health Research Announces Acquisition of ePatientFinder Clinical Trial Exchange Technology Platform and Practice Network
Advertisement
Austin, Texas, May 24, 2018 (Business Wire) -
Elligo Health Research
, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, has acquired
ePatientFinder’s
Clinical Trial Exchange technology platform and referring practice network, which is the largest of its kind. This acquisition will enhance Elligo’s trial matching process by incorporating ePatientFinder’s technology platform. Using this platform, Elligo will streamline patient identification and feasibility through automation using electronic health record (EHR) data within Elligo’s network of providers. “We believe this is an important strategic opportunity for Elligo to expand our technology and network growth capabilities,” said
John Potthoff
, PhD, CEO of Elligo Health Research. “ePatientFinder provides a technology platform and partnership ecosystem that will enable us to automate our EHR data analytics capabilities and expand our network of Research Ready™ sites to further benefit physicians, patients and sponsors.” Elligo implements its
Goes Direct™
approach to provide physicians with the personnel, procedures, technology and infrastructure to conduct trials in
Research Ready™
sites. This makes clinical trials more efficient and cost-effective, allowing patients to gain access to treatment options, enabling physicians to avoid the expenditure and effort of managing in-house infrastructure, and making it easier for sponsors to bring new therapies to market faster.
About Elligo
Elligo Health Research
offers the only platform that brings clinical research to physician practices, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Our Goes Direct™ approach uses state-of-the-art elliGO DIRECT™ technology to compliantly leverage current electronic health record data and applies a proprietary, prescreening process to match protocol-eligible patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at
elligodirect.com
.
Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Where AI Governance in Clinical Development Falls Short
3
Syneos Health, Optum Partner on Adaptive Clinical Development Model
4
ACT Brief: Applied Clinical Trials at 2026 SCRS Global Site Solutions Summit
5